Targeting CAMK1D-engineered nanoactivator suppresses cancer stem cell maintenance and immune evasion in enzalutamide-resistant prostate cancer
Year: 2025
Type: article
Abstract: Overall, the CD44-targeted EC@HNA nanoplatform disrupted stemness programs and restored tumor-immune surveillance, representing a promising strategy to reverse ENZR and potentiate immunotherapy in clinical ENZR PCa patients.
Source: Theranostics
DOI: 10.7150/thno.120826
Authors: Feifei Sun, Yuchuan Yan, Deqing Sun, Shijia Liu, Zhaoru Dong, Guoqiang Pan, Lin Zhang, Xianhao Shao, Yuliang Xu, Ying Qu, Tao Li
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,671
OpenAlex ID: W4417453388